title: GH therapy in juvenile chronic arthritis: results of a two-year controlled study on growth and bone.
abstract: Disturbance of growth frequently occurs in children suffering from juvenile chronic arthritis (JCA). Recognition of growth impairment is important because reduced final height is one of the permanent consequences. The aim of this study was to evaluate the efficacy and safety of human GH (hGH) in growth-retarded prepubertal children with JCA. Thirty-five children were tested for GH deficiency (GHD) and randomly assigned to a study and an untreated control group; five were GH deficient and were part of the GHD group. All received glucocorticoids. The study group was treated with 1 IU/kg BW.wk hGH; the GHD group was given 0.5 IU. During 2 yr of hGH treatment growth velocity and height SD score increased compared with baseline values. There was a marked increase in growth velocity in the treated groups, but also some increase in the control group. Plasma levels of IGF-I and IGF-binding protein-3 increased with GH treatment. These results suggest that hGH might be useful in the treatment of growth impairment in JCA. GH may counteract the adverse effects of glucocorticoid therapy, but its effect is dependent on the disease activity. Long-term controlled studies are needed to determine the risks and benefits of GH therapy in JCA.
authors.affiliation: Endocrine Division University Children's Hospital, D-80337 Munich, Germany. susanne.bechtold@kk-i.med.uni-muenchen.de
authors.forename: S
authors.initials: S
authors.lastname: Bechtold
authors.forename: P
authors.initials: P
authors.lastname: Ripperger
authors.forename: D
authors.initials: D
authors.lastname: Mühlbayer
authors.forename: H
authors.initials: H
authors.lastname: Truckenbrodt
authors.forename: R
authors.initials: R
authors.lastname: Häfner
authors.forename: O
authors.initials: O
authors.lastname: Butenandt
authors.forename: H P
authors.initials: HP
authors.lastname: Schwarz
mesh_terms: D001171:Arthritis, Juvenile / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D001846:Bone Development / Q000187:drug effects; D002648:Child; D002657:Child Development / Q000187:drug effects; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006130:Growth Disorders / Q000188:drug therapy* / Q000209:etiology*; D006728:Hormones / Q000097:blood; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008297:Male
chemical_list: D005938:Glucocorticoids; D006728:Hormones; D018972:Insulin-Like Growth Factor Binding Protein 3; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I